Suppr超能文献

三尖瓣反流患者经导管与外科三尖瓣修复术的比较:两年结果

Comparison of Transcatheter Versus Surgical Tricuspid Repair Among Patients With Tricuspid Regurgitation: Two-Year Results.

作者信息

Shimoda Tomonari M, Ueyama Hiroki A, Miyamoto Yoshihisa, Watanabe Atsuyuki, Gotanda Hiroshi, Kolte Dhaval, Latib Azeem, Kaneko Tsuyoshi, Zajarias Alan, Elmariah Sammy, Takayama Hiroo, Tsugawa Yusuke, Kuno Toshiki

机构信息

Department of Medicine, University of Tsukuba Hospital, Ibaraki, Japan (T.M.S.).

Division of Cardiology, Emory University School of Medicine, Atlanta, GA (H.A.U.).

出版信息

Circ Cardiovasc Interv. 2025 Jan;18(1):e014825. doi: 10.1161/CIRCINTERVENTIONS.124.014825. Epub 2024 Nov 18.

Abstract

BACKGROUND

Evidence is limited as to whether outcomes differ between patients with tricuspid regurgitation (TR) treated with tricuspid transcatheter edge-to-edge repair (T-TEER) versus surgical tricuspid valve repair. We aimed to compare outcomes between these 2 approaches.

METHODS

We analyzed the data on Medicare fee-for-service beneficiaries aged 65 to 99 years with TR who underwent T-TEER or isolated surgical repair between July 2016 and December 2020. The primary outcome was 2-year all-cause mortality. Other outcomes included in-hospital mortality and permanent pacemaker implantation as well as 2-year heart failure hospitalization and tricuspid valve reintervention. A propensity score matching weight analysis was used to adjust for potential confounders.

RESULTS

A total of 1143 patients were included (409 T-TEER versus 734 surgery). The proportion of T-TEER cases increased from 2% in the third quarter of 2016 to 67% in the last quarter of 2020 among all isolated TR procedures. After adjustment for potential confounders, we found no evidence that 2-year all-cause mortality differs between patients treated with T-TEER versus surgical repair (adjusted hazard ratio, 0.84 [95% CI, 0.63-1.13]). Patients treated with T-TEER experienced lower in-hospital mortality (2.5% versus 12.5%, <0.001) and permanent pacemaker implantation rates (0.0% versus 12.7%, <0.001) than those treated by surgical repair. At 2 years, we found no differences in heart failure hospitalizations, but tricuspid valve reinterventions were more frequent in the T-TEER group (subdistribution hazard ratio, 8.03 [95% CI, 2.87-22.48]).

CONCLUSIONS

Among Medicare beneficiaries with TR, the 2-year mortality rate was comparable between T-TEER and surgical repair. T-TEER showed advantages in perioperative outcomes, including lower in-hospital mortality and pacemaker implantation rates, whereas tricuspid valve reinterventions were more frequent in the T-TEER group. Further studies are necessary to refine indications, patient selections, and optimal timing for intervention with either treatment strategy.

摘要

背景

关于接受经导管三尖瓣缘对缘修复术(T-TEER)与外科三尖瓣修复术治疗的三尖瓣反流(TR)患者的预后是否存在差异,证据有限。我们旨在比较这两种治疗方法的预后。

方法

我们分析了2016年7月至2020年12月期间年龄在65至99岁、患有TR且接受T-TEER或单纯外科修复术的医疗保险按服务收费受益人的数据。主要结局是2年全因死亡率。其他结局包括住院死亡率、永久起搏器植入以及2年心力衰竭住院率和三尖瓣再次干预。采用倾向评分匹配权重分析来调整潜在混杂因素。

结果

共纳入1143例患者(409例行T-TEER,734例行手术)。在所有单纯TR手术中,T-TEER病例的比例从2016年第三季度的2%增至2020年最后一个季度的67%。在调整潜在混杂因素后,我们发现没有证据表明接受T-TEER治疗的患者与接受外科修复术的患者在2年全因死亡率上存在差异(调整后风险比,0.84[95%CI,0.63 - 1.13])。与接受外科修复术的患者相比,接受T-TEER治疗的患者住院死亡率更低(2.5%对12.5%,<0.001),永久起搏器植入率也更低(0.0%对12.7%,<0.001)。在2年时,我们发现心力衰竭住院率无差异,但T-TEER组三尖瓣再次干预更频繁(亚分布风险比,8.03[95%CI,2.87 - 22.48])。

结论

在患有TR的医疗保险受益人中,T-TEER和外科修复术的2年死亡率相当。T-TEER在围手术期结局方面显示出优势,包括较低的住院死亡率和起搏器植入率,而T-TEER组三尖瓣再次干预更频繁。需要进一步研究以完善两种治疗策略的适应证、患者选择和最佳干预时机。

相似文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验